Related Experiment Video
Updated: Apr 18, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.6K
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended
Adnan M Bhopalwala1, Robert A Hong1, Zia R Khan1
1The Queen's Medical Center, Honolulu, HI.
Summary
Genetic screening for CYP2C19 polymorphisms in clopidogrel-treated patients is of interest, particularly in Hawai
Area of Science:
- Pharmacogenomics
- Cardiology
- Clinical Chemistry
Background:
- Clopidogrel, an antiplatelet agent, requires bioactivation by Cytochrome P-450 (CYP) 2C19.
- CYP2C19 loss-of-function polymorphisms are more prevalent in Asian and Pacific Island populations.
- This has spurred interest in genetic testing for CYP2C19 in Hawai'i.
Purpose of the Study:
- To evaluate the utility of routine genetic screening for CYP2C19 polymorphisms in patients treated with clopidogrel.
- To determine if genetic testing results can guide antiplatelet therapy decisions.
Main Methods:
- Literature review of current evidence on CYP2C19 polymorphisms and clopidogrel treatment.
- Analysis of the clinical implications of genetic variations in drug metabolism.
Main Results:
- Current literature does not support routine genetic screening for CYP2C19 polymorphisms in clopidogrel-treated patients.
- Genetic testing results may not reliably inform therapeutic choices for antiplatelet therapy.
Conclusions:
- Routine CYP2C19 genetic screening is not recommended for patients on clopidogrel.
- Antiplatelet treatment decisions should prioritize clinical outcomes over genetic testing.
- Further research may be needed to clarify the role of pharmacogenomics in clopidogrel therapy.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
257
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
257
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
82
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
82
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
166
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
166